acetaminophen
Commercial- Indications
- Pain management, Fever reduction
Company intelligence / Profile preview
Cadence Pharmaceuticals successfully developed and commercialized OFIRMEV (acetaminophen) injection, the first and only intravenous formulation of acetaminophen approved in the U.S. The product received formulary acceptance at over 1,400 U.S. hospitals by October 2011, representing more than 60% of the targeted U.S. IV analgesic market opportunity. By 2013, the company had over 4,000 unique customer accounts, with net product revenue of $23.6 million in Q1 2013.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cadence Pharmaceuticals, Inc..